Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities

References

• Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 2016; 126(6):2123-38; PMID:27111235; http://dx.doi.org/10.1172/JCI85309
   PubMed Web of Science ®Google Scholar
• Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015; 385(9967):517-28; PMID:25319501; http://dx.doi.org/10.1016/S0140-6736(14)61403-3
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371(16):1507-17; PMID:25317870; http://dx.doi.org/10.1056/NEJMoa1407222
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev 2014; 257(1):83-90; PMID:24329791; http://dx.doi.org/10.1111/imr.12125
   PubMed Web of Science ®Google Scholar
• Hombach A, Sent D, Schneider C, Heuser C, Koch D, Pohl C, Seliger B, Abken H. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. Cancer Res 2001; 61(5):1976-82; PMID:11280755
   PubMed Web of Science ®Google Scholar
• Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med 2015; 21(8):914-21; PMID:26193344; http://dx.doi.org/10.1038/nm.3910
   PubMed Web of Science ®Google Scholar
• Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29(7):917-24; PMID:21282551; http://dx.doi.org/10.1200/JCO.2010.32.2537
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Li YF, El-Gamil M, Robbins PF, Rosenberg SA, Morgan RA. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res 2007; 67(8):3898-903; PMID:17440104; http://dx.doi.org/10.1158/0008-5472.CAN-06-3986
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res 2006; 66(17):8878-86; PMID:16951205; http://dx.doi.org/10.1158/0008-5472.CAN-06-1450
   PubMed Web of Science ®Google Scholar
• Ahmadi M, King JW, Xue SA, Voisine C, Holler A, Wright GP, Waxman J, Morris E, Stauss HJ. CD3 limits the efficacy of TCR gene therapy in vivo. Blood 2011; 118(13):3528-37; PMID:21750319; http://dx.doi.org/10.1182/blood-2011-04-346338
   PubMed Web of Science ®Google Scholar
• Heemskerk MH, Hagedoorn RS, van der Hoorn MA, van der Veken LT, Hoogeboom M, Kester MG, Willemze R, Falkenburg JH. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood 2007; 109(1):235-43; PMID:16968899; http://dx.doi.org/10.1182/blood-2006-03-013318
   PubMed Web of Science ®Google Scholar
• Kuball J, Dossett ML, Wolfl M, Ho WY, Voss RH, Fowler C, Greenberg PD. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 2007; 109(6):2331-8; PMID:17082316; http://dx.doi.org/10.1182/blood-2006-05-023069
   PubMed Web of Science ®Google Scholar
• Bendle GM, Linnemann C, Hooijkaas AI, Bies L, de Witte MA, Jorritsma A, Kaiser AD, Pouw N, Debets R, Kieback E et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med 2010; 16(5):565-70, 1p following 70; PMID:20400962; http://dx.doi.org/10.1038/nm.2128
   PubMed Web of Science ®Google Scholar
• Ghorashian S, Velica P, Chua I, McNicol AM, Carpenter B, Holler A, Nicholson E, Ahmadi M, Zech M, Xue SA et al. CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor. J Immunol 2015; 194(3):1080-9; PMID:25539815; http://dx.doi.org/10.4049/jimmunol.1401703
   PubMed Web of Science ®Google Scholar
• Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, Reik A, Chu V, Paschon DE, Zhang L, Kuball J et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med 2012; 18(5):807-15; PMID:22466705; http://dx.doi.org/10.1038/nm.2700
   PubMed Web of Science ®Google Scholar
• Sebestyen Z, Schooten E, Sals T, Zaldivar I, San Jose E, Alarcon B, Bobisse S, Rosato A, Szöllosi J, Gratama JW et al. Human TCR that incorporate CD3zeta induce highly preferred pairing between TCRalpha and beta chains following gene transfer. J Immunol 2008; 180(11):7736-46; PMID:18490778; http://dx.doi.org/10.4049/jimmunol.180.11.7736
   PubMed Web of Science ®Google Scholar
• Govers C, Sebestyen Z, Roszik J, van Brakel M, Berrevoets C, Szoor A, Panoutsopoulou K, Broertjes M, Van T, Vereb G et al. TCRs genetically linked to CD28 and CD3epsilon do not mispair with endogenous TCR chains and mediate enhanced T cell persistence and anti-melanoma activity. J Immunol 2014; 193(10):5315-26; PMID: 25320284; http://dx.doi.org/10.4049/jimmunol.1302074
   PubMed Web of Science ®Google Scholar
• Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013; 36(2):133-51; PMID:23377668; http://dx.doi.org/10.1097/CJI.0b013e3182829903
   PubMed Web of Science ®Google Scholar
• Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013; 122(6):863-71; PMID:23770775; http://dx.doi.org/10.1182/blood-2013-03-490565
   PubMed Web of Science ®Google Scholar
• Schaft N, Lankiewicz B, Drexhage J, Berrevoets C, Moss DJ, Levitsky V, Bonneville M, Lee SP, McMichael AJ, Gratama JW et al. T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNgamma production. Int Immunol 2006; 18(4):591-601; PMID:16507598; http://dx.doi.org/10.1093/intimm/dxh401
   PubMed Web of Science ®Google Scholar
• Maude SL, Shpall EJ, Grupp SA. Chimeric antigen receptor T-cell therapy for ALL. Hematol: Am Soc Hematol Educ Prog 2014; 2014(1):559-64; http://dx.doi.org/10.1182/asheducation-2014.1.559
   PubMed Web of Science ®Google Scholar
• Lamers CH, Klaver Y, Gratama JW, Sleijfer S, Debets R. Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview. Biochem Soc Trans 2016; 44(3):951-9; PMID:27284065; http://dx.doi.org/10.1042/BST20160037
   PubMed Web of Science ®Google Scholar
• Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, Diouf O, Liu E, Barrett AJ, Ito S et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 2013; 122(17):2965-73; PMID:24030379; http://dx.doi.org/10.1182/blood-2013-06-506741
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 2013; 122(25):4129-39; PMID:24055823; http://dx.doi.org/10.1182/blood-2013-08-519413
   PubMed Web of Science ®Google Scholar
• Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH, Gea-Banacloche JC, Pavletic SZ, Hickstein DD, Lu TL et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-Cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol 2016; 34(10):1112-21; PMID:26811520; http://dx.doi.org/10.1200/JCO.2015.64.5929
   PubMed Web of Science ®Google Scholar
• Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, Butler K, Rivat C, Wright G, Somana K, Ghorashian S, Pinner D, Ahsan G, Gilmour K, Lucchini G, Inglott S, Mifsud W, Chiesa R, Peggs KS, Chan L, Farzeneh F, Thrasher AJ, Vora A, Pule M, Veys P et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017; 9(374)pii:eaaj2013; PMID:28123068; http://dx.doi.org/10.1126/scitranslmed.aaj2013
   Google Scholar
• Snauwaert S, Verstichel G, Bonte S, Goetgeluk G, Vanhee S, Van Caeneghem Y et al. In vitro generation of mature, naive antigen-specific CD8(+) T cells with a single T-cell receptor by agonist selection. Leukemia 2014; 28(4):830-41; PMID:24091848; http://dx.doi.org/10.1038/leu.2013.285
   PubMed Web of Science ®Google Scholar
• Van Coppernolle S, Verstichel G, Timmermans F, Velghe I, Vermijlen D, De Smedt M, Leclercq G, Plum J, Taghon T, Vandekerckhove B et al. Functionally mature CD4 and CD8 TCRalphabeta cells are generated in OP9-DL1 cultures from human CD34+ hematopoietic cells. J Immunol 2009; 183(8):4859-70; PMID:19801512; http://dx.doi.org/10.4049/jimmunol.0900714
   PubMed Web of Science ®Google Scholar
• De Smedt M, Taghon T, Van de Walle I, De Smet G, Leclercq G, Plum J. Notch signaling induces cytoplasmic CD3 epsilon expression in human differentiating NK cells. Blood 2007; 110(7):2696-703; PMID:17630354; http://dx.doi.org/10.1182/blood-2007-03-082206
   PubMed Web of Science ®Google Scholar
• Kisielow P, Teh HS, Bluthmann H, von Boehmer H. Positive selection of antigen-specific T cells in thymus by restricting MHC molecules. Nature 1988; 335(6192):730-3; PMID:3262831; http://dx.doi.org/10.1038/335730a0
   PubMed Web of Science ®Google Scholar
• Vatakis DN, Arumugam B, Kim SG, Bristol G, Yang O, Zack JA. Introduction of exogenous T-cell receptors into human hematopoietic progenitors results in exclusion of endogenous T-cell receptor expression. Mol Ther 2013; 21(5):1055-63; PMID:23481324; http://dx.doi.org/10.1038/mt.2013.28
   PubMed Web of Science ®Google Scholar
• Giannoni F, Hardee CL, Wherley J, Gschweng E, Senadheera S, Kaufman ML, Kaufman ML, Chan R, Bahner I, Gersuk V, Wang X et al. Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells. Mol Ther 2013; 21(5):1044-54; PMID:23380815; http://dx.doi.org/10.1038/mt.2013.8
   PubMed Web of Science ®Google Scholar
• Nishimura T, Kaneko S, Kawana-Tachikawa A, Tajima Y, Goto H, Zhu D, Nakayama-Hosoya K, Iriguchi S, Uemura Y, Shimizu T. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell 2013; 12(1):114-26; PMID:23290140; http://dx.doi.org/10.1016/j.stem.2012.11.002
   PubMed Web of Science ®Google Scholar
• Vizcardo R, Masuda K, Yamada D, Ikawa T, Shimizu K, Fujii S, Koseki H, Kawamoto H. Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells. Cell Stem Cell 2013; 12(1):31-6; PMID:23290135; http://dx.doi.org/10.1016/j.stem.2012.12.006
   PubMed Web of Science ®Google Scholar
• Themeli M, Kloss CC, Ciriello G, Fedorov VD, Perna F, Gonen M, Sadelain M. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol 2013; 31(10):928-33; PMID:23934177; http://dx.doi.org/10.1038/nbt.2678
   PubMed Web of Science ®Google Scholar
• Zakrzewski JL, Suh D, Markley JC, Smith OM, King C, Goldberg GL, Jenq R, Holland AM, Grubin J, Cabrera-Perez J et al. Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat Biotechnol 2008; 26(4):453-61; PMID:18376399; http://dx.doi.org/10.1038/nbt1395
   PubMed Web of Science ®Google Scholar
• Zhen A, Kamata M, Rezek V, Rick J, Levin B, Kasparian S, Chen IS, Yang OO, Zack JA, Kitchen SG. HIV-specific immunity derived from chimeric antigen receptor-engineered Stem Cells. Mol Ther 2015; 23(8):1358-67; PMID:26050990; http://dx.doi.org/10.1038/mt.2015.102
   PubMed Web of Science ®Google Scholar
• Crompton JG, Rao M, Restifo NP. Memoirs of a reincarnated T cell. Cell Stem Cell 2013; 12(1):6-8; PMID:23290132; http://dx.doi.org/10.1016/j.stem.2012.12.009
   PubMed Web of Science ®Google Scholar
• Clancy LE, Blyth E, Simms RM, Micklethwaite KP, Ma CK, Burgess JS, Antonenas V, Shaw PJ, Gottlieb DJ. Cytomegalovirus-specific cytotoxic T lymphocytes can be efficiently expanded from granulocyte colony-stimulating factor-mobilized hemopoietic progenitor cell products ex vivo and safely transferred to stem cell transplantation recipients to facilitate immune reconstitution. Biol Blood Marrow Transplant 2013; 19(5):725-34; PMID:23380344; http://dx.doi.org/10.1016/j.bbmt.2013.01.021
   PubMed Web of Science ®Google Scholar
• Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, Seliger B, Abken H. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol 2001; 167(11):6123-31; PMID:11714771; http://dx.doi.org/10.4049/jimmunol.167.11.6123
   PubMed Web of Science ®Google Scholar
• Schaft N, Willemsen RA, de Vries J, Lankiewicz B, Essers BW, Gratama JW, Figdor CG, Bolhuis RL, Debets R, Adema GJ. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J Immunol 2003; 170(4):2186-94; PMID:12574392; http://dx.doi.org/10.4049/jimmunol.170.4.2186
   PubMed Web of Science ®Google Scholar
• Willemsen RA, Weijtens ME, Ronteltap C, Eshhar Z, Gratama JW, Chames P, Bolhuis RL. Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Therapy 2000; 7(16):1369-77; PMID:10981663; http://dx.doi.org/10.1038/sj.gt.3301253
   PubMed Web of Science ®Google Scholar
• De Smedt M, Hoebeke I, Plum J. Human bone marrow CD34+ progenitor cells mature to T cells on OP9-DL1 stromal cell line without thymus microenvironment. Blood Cells Mol Dis 2004; 33(3):227-32; PMID:15528136; http://dx.doi.org/10.1016/j.bcmd.2004.08.007
   PubMed Web of Science ®Google Scholar
• Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin Invest 2014; 124(5):2246-59; PMID:24667641; http://dx.doi.org/10.1172/JCI73639
   PubMed Web of Science ®Google Scholar
• Bolotin DA, Poslavsky S, Mitrophanov I, Shugay M, Mamedov IZ, Putintseva EV, Chudakov DM. MiXCR: Software for comprehensive adaptive immunity profiling. Nat Methods 2015; 12(5):380-1; PMID:25924071; http://dx.doi.org/10.1038/nmeth.3364
   PubMed Web of Science ®Google Scholar
• Shugay M, Bagaev DV, Turchaninova MA, Bolotin DA, Britanova OV, Putintseva EV, Pogorelyy MV, Nazarov VI, Zvyagin IV, Kirgizova VI et al. VDJtools: unifying post-analysis of T cell receptor repertoires. PLoS Comput Biol 2015; 11(11):e1004503; PMID:26606115; http://dx.doi.org/10.1371/journal.pcbi.1004503
   PubMed Web of Science ®Google Scholar